In IVF/ICSI cycles, progesterone levels prompted
by ovarian stimulation are low; therefore the luteal phase is supported by
progesterone. A standard protocol for luteal phase support has not yet been
established. There is currently a wide use of vaginal progesterone, since oral
progesterone results in lower pregnancy rates. However, vaginal administration
of progesterone is associated with several adverse events such as vaginal
irritation, discharge and bleeding. For all these reasons, there is a need for
an effective, well tolerated, and safe treatment that can improve patient
satisfaction and compliance. The objective of our study is to compare the use
oral dydrogesterone (Duphaston) and vaginal progesterone (Utrogestan) for
luteal supplementation in cryo-warmed embryo transfer cycles, along with the
potential adverse events or harm associated with each.
This retrospective observational study will review the archived charts of all of
Dr. Johnny Awwad’s patients who underwent cryo-warmed embryo transfer cycles at
the AUBMC Fertility Center at the American University of Beirut Medical Center
between August 2016 and August 2018
Age: 18-42 years at the time of interview.
Normal uterine cavity (as assessed by hysteroscopy or HSG).
Normal hormonal investigation: TSH, PRL.
Undergoing a cryo-warmed embryo transfer cycle
Body mass index (BMI) ≥18 to ≤30 kg/m2 .
Preexisting untreated medical condition (thyroid
disease, diabetes mellitus, hypertension, pulmonary conditions, cardiac
History of three or more previous IVF failures.
History of three or more miscarriages.
Previous allergy reactions to progesterone products.